Valuation
- Market cap
- 150,535,000
- Revenue TTM
- $0
- Net income TTM
- $-4,670,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.74
Trading
- Volume
- 41,200
- Avg volume
- 41,244
- Day's range
- $1.80 – $2.02
- Shares out
- 76,028,000
- Stochastic %K
- 11%
- Beta
- 2.38
- Analysts
- Strong Buy
- Price target
- —
Company profile
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bl...
Show more
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 886 2 2732 5205
- Website
- https://jyongbio.com
- Address
- No. 95, Xintai 5th Road, 23F-3 Section 1 Xizhi District, New Taipei City, Taiwan
Latest news
No headlines yet.
